Dr. Omar Mian, MD PhD
Claim this profileCleveland Clinic, Case Comprehensive Cancer Center
Studies Thyroid Cancer
Studies Bladder Cancer
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Omar Mian, MD PhD is currently running
18F-Clofarabine PET Imaging
for Cancer
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.
Recruiting1 award Phase < 1
SG + Radiation Therapy
for Bladder Cancer
The purpose of this study is to examine the safety and tolerability of treatment with concurrent Sacituzumab Govitecan (SG) and adaptive radiation therapy. The main objective is to establish the safety, tolerability, and feasibility of bladder preservation therapy treatment with concurrent SG and adaptive image-guided radiation therapy for participants with localized MIBC. Participants will receive the study drug, SG, through an IV once weekly on days 1 and 8 of each 21-day treatment cycle. The first cycle of SG will begin 21 days prior to the scheduled start of radiation therapy. The second and third cycles of SG will be given while the participant is receiving radiation therapy. Participants will be asked to undergo computed tomography (CT) and magnetic resonance imaging (MRI) pre-and post-treatment. Participation in the research will last up to 5 years, depending on treatment outcomes, with a treatment period of 8 weeks and a study follow-up period of up to 2-5 years thereafter, and a survival follow-up, with only phone call communication from years 3-5.
Recruiting1 award Phase 110 criteria
More about Omar Mian, MD PhD
Clinical Trial Related2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Omar Mian, MD PhD has experience with
- Adaptive Radiotherapy
- Sacituzumab Govitecan
- 18F-Clofarabine
Breakdown of trials Omar Mian, MD PhD has run
Thyroid Cancer
Bladder Cancer
Metastases
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Omar Mian, MD PhD specialize in?
Omar Mian, MD PhD focuses on Thyroid Cancer and Bladder Cancer. In particular, much of their work with Thyroid Cancer has involved treating patients, or patients who are undergoing treatment.
Is Omar Mian, MD PhD currently recruiting for clinical trials?
Yes, Omar Mian, MD PhD is currently recruiting for 2 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Omar Mian, MD PhD has studied deeply?
Yes, Omar Mian, MD PhD has studied treatments such as Adaptive Radiotherapy, Sacituzumab Govitecan, 18F-Clofarabine.
What is the best way to schedule an appointment with Omar Mian, MD PhD?
Apply for one of the trials that Omar Mian, MD PhD is conducting.
What is the office address of Omar Mian, MD PhD?
The office of Omar Mian, MD PhD is located at: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio 44106 United States. This is the address for their practice at the Cleveland Clinic, Case Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.